These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36274045)

  • 21. Cystic Fibrosis-Related Pancreatic Cysts Decrease in Size and Number Upon Treatment With Cystic Fibrosis Transmembrane Conductance Regulator Modulators.
    de Vries JM; Green D; Kucera JN; Fabbrini AL; Kidder M; Brown J; Wilsey M
    Pancreas; 2020 Jul; 49(6):e50-e51. PubMed ID: 32590622
    [No Abstract]   [Full Text] [Related]  

  • 22. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
    Ong T; Ramsey BW
    Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion.
    Colombo C; Foppiani A; Bisogno A; Gambazza S; Daccò V; Nazzari E; Leone A; Giana A; Mari A; Battezzati A
    J Endocrinol Invest; 2021 Oct; 44(10):2213-2218. PubMed ID: 33586024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Combined administration of lumacaftor and ivacaftor as a causal therapeutic approach].
    Desch M
    Med Monatsschr Pharm; 2016 Jan; 39(1):42-4. PubMed ID: 26975180
    [No Abstract]   [Full Text] [Related]  

  • 25. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
    Rehman A; Baloch NU; Janahi IA
    N Engl J Med; 2015 Oct; 373(18):1783. PubMed ID: 26510035
    [No Abstract]   [Full Text] [Related]  

  • 26. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
    Wainwright CE; Elborn JS; Ramsey BW
    N Engl J Med; 2015 Oct; 373(18):1783-4. PubMed ID: 26510034
    [No Abstract]   [Full Text] [Related]  

  • 27. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.
    Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET
    Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radical new treatments for cystic fibrosis.
    Arch Dis Child; 2015 Aug; 100(8):727. PubMed ID: 26078470
    [No Abstract]   [Full Text] [Related]  

  • 29. A new triple combination cystic fibrosis transmembrane regulator modulator.
    Perrem L; Ratjen F
    Lancet Respir Med; 2023 Jun; 11(6):499-500. PubMed ID: 36842448
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of lumacaftor-ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis: Results from the PROSPECT MCC sub-study.
    Donaldson SH; Laube BL; Mogayzel P; Corcoran TE; Pilewski JM; Ceppe A; Wu J; Bhambhvani PG; Ratjen F; Sagel SD; Clancy JP; Rowe SM; Bennett WD
    J Cyst Fibros; 2022 Jan; 21(1):143-145. PubMed ID: 34083123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.
    Bulloch MN; Hanna C; Giovane R
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study.
    Bell SC; Mainz JG; MacGregor G; Madge S; Macey J; Fridman M; Suthoff ED; Narayanan S; Kinnman N
    BMC Pulm Med; 2019 Aug; 19(1):146. PubMed ID: 31409396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lumacaftor/ivacaftor in people with cystic fibrosis with an A455E-CFTR mutation.
    Berkers G; van der Meer R; Heijerman H; Beekman JM; Boj SF; Vries RGJ; van Mourik P; Doyle JR; Audhya P; Yuan ZJ; Kinnman N; van der Ent CK
    J Cyst Fibros; 2021 Sep; 20(5):761-767. PubMed ID: 33249003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis.
    McCarthy C; Brewington JJ; Harkness B; Clancy JP; Trapnell BC
    Eur Respir J; 2018 Jun; 51(6):. PubMed ID: 29563174
    [No Abstract]   [Full Text] [Related]  

  • 36. Negotiations between the NHS and Vertex on access to lumacaftor and ivacaftor become protracted.
    Burki TK
    Lancet Respir Med; 2019 Sep; 7(9):739-740. PubMed ID: 31353281
    [No Abstract]   [Full Text] [Related]  

  • 37. Drug allergy to CFTR modulator therapy associated with lumacaftor-specific CD4
    Roehmel JF; Ogese MO; Rohrbach A; Mall MA; Naisbitt DJ
    J Allergy Clin Immunol; 2021 Feb; 147(2):753-756. PubMed ID: 32526307
    [No Abstract]   [Full Text] [Related]  

  • 38. Update in Cystic Fibrosis 2014.
    Ong T; Ramsey BW
    Am J Respir Crit Care Med; 2015 Sep; 192(6):669-75. PubMed ID: 26371812
    [No Abstract]   [Full Text] [Related]  

  • 39. Unexpected analytical interference in isavuconazole UV determination in a child in therapy with lumacaftor/ivacaftor for cystic fibrosis.
    Baldelli S; Fusi M; Cozzi V; Clementi E; Faelli NML; Russo M; Colombo C; Cattaneo D
    Clin Chem Lab Med; 2019 Oct; 57(11):e274-e278. PubMed ID: 31141479
    [No Abstract]   [Full Text] [Related]  

  • 40. Pregnancy among cystic fibrosis women in the era of CFTR modulators.
    Heltshe SL; Godfrey EM; Josephy T; Aitken ML; Taylor-Cousar JL
    J Cyst Fibros; 2017 Nov; 16(6):687-694. PubMed ID: 28190780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.